Determining patient preferences in the treatment of medication‐refractory overactive bladder

Overactive bladder (OAB) is often suboptimally addressed by behavioural or pharmacological treatments. Less than 15% of patients choose to pursue advanced OAB therapy (sacral nerve stimulation [SNS], percutaneous tibial nerve stimulation [PTNS], and bladder onabotulinum toxin type‐A [BTX‐A]). We seek to understand the factors most important to patients when choosing a third‐line therapy. Frequent follow‐up, risk of catheterization, and the need for a device were the most important attributes when deciding on third‐line OAB therapy. On market simulation, SNS is the preferred treatment for all age groups. However, the ultimate choice in third‐line medicine may be affected by external factors.